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MaBACKGROUND Recent large clinical trials show lower rates of late cardiovascular events by extending clopidogrel
>12 months after percutaneous coronary revascularization (PCI). However, concerns of increased bleeding have elicited
support for limiting prolonged treatment to high-risk patients.
OBJECTIVES The aim of this analysis was to determine the effect of prolonging clopidogrel therapy >12 months
versus #12 months after PCI on very late outcomes in patients with diabetes mellitus (DM).
METHODS Using the Veterans Health Administration, 28,849 patients undergoing PCI between 2002 and 2006 were
categorized into 3 groups: 1) 16,332 without DM; 2) 9,905 with DM treated with oral medications or diet; and 3) 2,612
with DM treated with insulin. Clinical outcomes, stratiﬁed by stent type, #4 years after PCI were determined from the
Veterans Health Administration and Medicare databases and risk was assessed by multivariable and propensity score
analyses using a landmark analysis starting 1 year after the index PCI. The primary endpoint of the study was the
risk of all-cause death or myocardial infarction (MI).
RESULTS In patients with DM treated with insulin who received drug-eluting stents (DES), prolonged clopidogrel
treatment was associated with a decreased risk of death (hazard ratio [HR]: 0.59; 95% conﬁdence interval [CI]: 0.42 to
0.82) and death or MI (HR: 0.67; 95% CI: 0.49 to 0.92). Similarly, in patients with noninsulin-treated DM receiving DES,
prolonged clopidogrel treatment was associated with less death (HR: 0.61; 95% CI: 0.48 to 0.77) and death or MI
(HR: 0.61; 95% CI: 0.5 to 0.75). Prolonged clopidogrel treatment was not associated with a lower risk in patients without
DM or in any group receiving bare-metal stents.
CONCLUSIONS Extending the duration of clopidogrel treatment >12 months may decrease very late death or MI only in
patients with DM receiving ﬁrst-generation DES. Future studies should address this question in patients receiving second-
generation DES. (J Am Coll Cardiol 2015;66:1091–101) © 2015 by the American College of Cardiology Foundation.m the *Cardiovascular Division, Veterans Affairs Boston Healthcare System, Boston, Massachusetts; yCardiovascular Division,
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ABBR EV I A T I ON S
AND ACRONYMS
BMS = bare-metal stent(s)
CABG = coronary artery
bypass grafting
CI = conﬁdence interval
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
DM = diabetes mellitus
HR = hazard ratio
ICD-9 = International
Classiﬁcation of Diseases-
Ninth Revision
MI = myocardial infarction
PCI = percutaneous coronary
intervention
VA = Veterans Affairs
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1092T he duration of clopidogrel therapyafter percutaneous coronary inter-vention (PCI) remains a vexing issue.
Older studies showed that discontinuing dual
antiplatelet therapy (DAPT) in the ﬁrst 12
months after PCI increased the risk of
myocardial infarction (MI), stent thrombosis,
and death and led to the current recommen-
dations of DAPT for $1 year (1). More
recently, the DAPT study showed that in pa-
tients free of ischemic and major bleeding
events in the ﬁrst year after PCI, prolonging
DAPT a further 18 months reduced recurrent
ischemic events (2,3). However, concerns of
harm from increased bleeding and the results
of several smaller studies supporting shorter
term DAPT (4–10) have generated uncer-
tainty, with suggestions of individualizing
DAPT duration according to clinical judg-ment of perceived risks and beneﬁts (11). Exactly
which patient characteristics should be used to deter-
mine prolonged DAPT remains unclear.SEE PAGE 1102Diabetes mellitus (DM) is consistently identiﬁed as
a risk factor for poorer outcomes after PCI (12–14). DM
could be an important determinant of DAPT duration.
The aims of this analysis were to assess whether DM
could serve as a clinical indicator of beneﬁt of
prolonging DAPT >12 months after PCI.
METHODS
PATIENT POPULATION. We identiﬁed all patients
who received coronary stents at any Veterans Affairs
(VA) facility in the United States between April 2002
and September 2006 and who were alive 12 months
after their index PCI (15). We used the International
Classiﬁcation of Diseases-Ninth Revision (ICD-9)
procedure codes for coronary artery stent placement
(36.06 for bare-metal stents [BMS] and 36.07 for
drug-eluting stents [DES]) to identify patients. Dur-
ing this time frame, only ﬁrst-generation DES were
available. The index procedure was deﬁned as the
ﬁrst coronary artery stent procedure between 2002
and 2006. Of 42,254 patients receiving coronary
stents, 2,930 (7%) died within 12 months of their in-
dex PCI (Figure 1). We excluded another 10,475
patients, as outlined in Figure 1. Subjects free of
the clinical outcomes at 1 year were followed to
September 1, 2007, with a maximum follow-up of
4 years after their index PCI.
DEMOGRAPHIC DATA. Data from the time of the
index procedure included the patient age, sex, race,and presentation with an acute coronary syndrome.
Comorbid conditions were deﬁned by ICD-9 codes as
those from 5 years before 12 months after the index
PCI and included previous angioplasty (ICD-9: 36.01-2,
36.05-7,00.66), coronary bypass surgery (ICD-9: 36.1),
smoking (ICD-9: 305.1), hypertension (ICD-9: 401),
congestive heart failure (ICD-9: 428), previous stroke
(ICD-9: 433.01, 433.11, 434.91, 436, V1254), peripheral
arterial disease (ICD-9: 443), chronic obstructive lung
disease (ICD-9: 496), anemia (ICD-9: 281-285), and
chronic kidney disease (ICD-9: 585).
CLASSIFICATION OF DM. Patients were classiﬁed
into 3 groups based on the ICD-9 codes for DM (250.x)
and use of outpatient hypoglycemic agents in the ﬁrst
12 months after the index PCI, including insulin
(VA drug classiﬁcation: HS501) or oral hypoglycemic
agents (VA drug classiﬁcation: HS502). These data
were used to stratify patients into the following
3 groups: 1) no ICD-9 code for DM (no DM group);
2) ICD-9 code for DM and treated with oral medications
or no medications (DM, no insulin group); and 3) ICD-9
code for DM and treated with insulin (DM and insulin).
MEDICATION USE. The VA National Pharmacy Data-
base provided medications used at the index PCI and
clopidogrel during the follow-up period. Because VA
prescriptions are usually written for 90-day periods,
we deﬁned baseline cardiovascular medications as
prescriptions ﬁlled within 90 days before the index
procedure to up to 7 days after the index procedure.
Aspirin use is a VA quality-control measure, and other
studies show very high rates of outpatient aspirin use
in VA patients with coronary artery disease (16). The
database tracks the dates of prescription and the
amount and delivery of clopidogrel up to 4 years
after their index PCI. If a clopidogrel prescription
lapsed >30 days from the last day of the supply,
the patient was considered to be not taking clopi-
dogrel. We deﬁned clopidogrel use as either pro-
longed (>12 months of use after the index PCI) or
#12 months of use after the index PCI.
OUTCOMES. Clinical outcomes after the index PCI
were identiﬁed from the Department of Veterans
Affairs National Patient Care, VA Death Database, and
the Centers for Medicaid and Medicare database
using ICD-9 codes until October 2007. These included
all-cause death, the combined outcome of death
or MI (ICD-9: 410), admissions with a new dis-
charge diagnosis of revascularization by PCI (ICD-9:
36.01, 36.02, 36.05, 00.66) or coronary artery bypass
grafting (CABG) (ICD-9:36.1), ischemic stroke (ICD-9:
436, 433.01, 433.11, 433.21, 433.31, 433.81, 433.91,
434.01, 434.11, 434.91), and hospitalization for severe
bleeding (ICD-9: rectal bleeding, 569.3; esophageal
FIGURE 1 Study Population
42,254 Subjects receiving DES or BMS
4/1/2002 – 9/30/2006
2930 Deaths in the First Year
28,849 Subjects
10,475 Excluded Consisting Of:
624 received both DES & BMS
1010 with CABG or PCI < 12 months
6612 on long-term clopidogrel for other reasons
931 No VA record of clopidogrel use within 90d of index PCI
871 using aspirin–dipyridamole or ticlopidine after index stent
390 cancer and chemotherapy within 12 months of index PCI
37 with no follow-up time
2,612 DM + Insulin 9,905 DM No Insulin 16,332 No DM
1,383 DES 1,229 BMS
5,043 DES 4,862 BMS
8,342 DES 7,990 BMS
573
≤ 12 month
810
> 12 month
784
≤ 12 month
445
> 12 month
2,129
≤ 12 month
2,914
> 12 month
3,082
≤ 12 month
1,780
> 12 month
3,753
≤ 12 month
4,589
> 12 month
5,430
≤ 12 month
2,560
> 12 month
Study population with exclusion criteria. BMS ¼ bare-metal stent(s); CABG ¼ coronary artery bypass grafting; DES ¼ drug-eluting stent(s); DM ¼ diabetes mellitus;
PCI ¼ percutaneous coronary intervention; VA ¼ Veterans Affairs.
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1093hemorrhage, 530.82; hematemesis, 578; gastro-
duodenitis with bleeding, 535.01- 535.61; intracranial
hemorrhage, 430-432; intraocular, 379.23; hemorrhage
not speciﬁed, 459).
STATISTICAL ANALYSIS. The primary endpoint was
the combined endpoint of death orMI in the 1 to 4 years
after PCI, with secondary outcomes of death alone,
repeat surgical or percutaneous coronary revasculari-
zation, ischemic stroke, or serious or life-threatening
bleeding. Because previous studies indicate different
outcomes in patients with DES versus BMS, the anal-
ysis was prospectively stratiﬁed by stent type.We used
event curves and landmark analyses to analyze out-
comes in subjects who were free of the outcome under
analysis 12 months after the index PCI. Patients were
followeduntil they died or had the outcomeof interest.
Follow-up was censored after September 2007, 12
months after the last recorded VA visit, or 4 years after
the index procedure. We calculated the hazard ratio
(HR) and 95% conﬁdence interval (CI) for prolonged
clopidogrel use versus clopidogrel #12 months foreach outcome within each stent and DM subgroup us-
ing Cox proportional hazards regression. Multivariable
models were developed from more than 50 variables
and included whether they were related to the
outcome of death or MI. The HR from the ﬁnal
multivariable models for each outcome were adjusted
for the baseline characteristics of age, hypertension,
smoking, acute coronary syndrome on admission,
peripheral vascular disease, chronic kidney disease,
congestive heart failure, warfarin use within 7 days of
the index procedure, and the year of stent placement.
The multivariable models excluded patients with the
outcome of interest in the ﬁrst year and also adjusted
for the other major outcomes in the ﬁrst year (e.g., the
HR for long-term death or MI excluded patients
with death or MI in the ﬁrst year and adjusted for
stroke, revascularization, or bleeding in the ﬁrst year).
We also used Cox models to assess stent type by
prolonged clopidogrel interactions within each DM
group. We used a second method of adjustment for
confounders by constructing propensity models for
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1094prolonged clopidogrel from statistically signiﬁcant
baseline characteristics using multivariable logistic
regression (15) (Online Table 1). We estimated HRs
for each outcome using inverse probability weighting
of the propensity score in the Cox proportional hazards
models. Sensitivity analyses included the following: 1)
repeating the analyses after excluding subjects with
any primary or secondary endpoint in the ﬁrst year to
simulate the patient selection in the DAPT trial (3); and
2) varying the deﬁnition of stopping clopidogrel from a
gap in treatment >30 days to a gap in treatment of >15
days and >60 days. To account for the multiple com-
parisons, statistical signiﬁcance was p <0.01.
RESULTS
After exclusions (Figure 1), the study popula-
tion consisted of 28,849 patients who were alive
12 months after their index PCI. Tables 1 and 2 show
baseline characteristics for all patients who received
PCI with DES (Table 1) or BMS (Table 2), by DM group
and duration of clopidogrel treatment.
Events for insulin-treated DM between the index PCI
and 1 year included MI in 7.6%, repeat revascularizationTABLE 1 Baseline Data for Patients Receiving DES for PCI by DM Gro
Insulin-Treated DM (n ¼ 1,383)
Clopidogrel duration, months #12 (n ¼ 573) >12 (n ¼ 810) #12
Age, yrs 63.9  9.0 64.7  9.9 6
Men 799 (98.6) 2,092 (98.3) 2,
Comorbidities 5 yrs before to
1 yr after index procedure
Smoking 181 (31.6) 253 (31.2) 8
Previous MI 195 (34.0) 284 (35.1)
Angina 239 (41.7) 375 (46.3)
Hypertension 564 (98.4) 798 (98.5) 2,
COPD 173 (30.2) 267 (33.0)
CKD 132 (23.0) 190 (23.5) 2
PVD 189 (33.0) 252 (31.1)
Anemia, Hb <12 mg/dl 146 (27.4) 178 (22.0)
Stroke 52 (9.1) 61 (7.5)
Heart failure 268 (46.8) 390 (48.2)
Previous CABG 22 (3.8) 21 (2.6)
Previous PCI 19 (3.3) 18 (2.2)
ACS on index admission 322 (56.2) 479 (59.1) 1,
Baseline medication
Statin or lipid-lowering agent 492 (85.9) 698 (86.2) 1,
Beta-blocker 538 (93.9) 769 (94.9) 1,
Calcium-channel blocker 529 (92.3) 745 (92.0) 1,
ACEI or ARB 193 (33.7) 286 (35.3)
PPI 444 (77.5) 634 (78.3) 1,
Warfarin 306 (53.4) 453 (55.9)
Values are mean  SD or n (%).
ACEI ¼ angiotensin-converting enzyme inhibitor; ACS ¼ acute coronary syndrome(s);
chronic kidney disease; COPD ¼ chronic obstructive pulmonary disease; DES ¼ drug-elu
PCI ¼ percutaneous coronary intervention; PPI ¼ proton pump inhibitor; PVD ¼ periphewith PCI or CABG in 17.3%, stroke in 1.0%, and major
bleeding in 1.8%. Events in the DM and no insulin group
between the index PCI and 1 year included MI in 5.4%,
repeat revascularizationwithPCI orCABG in 14.8%, stroke
in 0.4%, and severe bleeding in 1.2%. Events in the no DM
group between the index PCI and 1 year included MI in
4.4%, repeat revascularization with PCI or CABG in 11.7%,
stroke in 0.3%, and major bleeding in 1.2%. Among pa-
tients receiving DES, the mean durations of clopidogrel
use for patients in the>12 versus#12 months clopidogrel
groups were 18.5 versus 6.1 months for insulin-treated
DM, 17.9 versus 6.2 months for DM and no insulin, and
17.0 versus 6.2 months for no DM. Among patients
receiving BMS, the corresponding durations were 23.1
versus 3.0 months for insulin-treated DM, 22.3 versus 2.6
months forDMandno insulin, and20.0 versus 2.8months
for no DM.
RISK OF DEATH OR MI WITH DM VERSUS NO DM.
Among patients alive at 12 months, both DM groups had
higher rates of death or MI 1 to 4 years after PCI com-
pared with patients without DM. Among patients re-
ceiving DES, death or MI occurred in 150 (22%) of
patients with insulin-treated DM (HR: 1.97; p < 0.0001
compared with no DM), 393 (16%) with DM not requiringup and Duration of Clopidogrel Treatment
DM, No Insulin (n ¼ 5,043) No DM (n ¼ 8,342)
(n ¼ 2,129) >12 (n ¼ 2,914) #12 (n ¼ 3,753) <12 (n ¼ 4,589)
4.6  9.2 63.9  9.0 64.7  9.9 63.7  10.4
866 (98.4) 799 (98.6) 2,092 (98.3) 2,515 (98.2)
08 (38.0) 1,030 (35.4) 1,879 (50.1) 2,166 (47.2)
581 (27.3) 917 (31.5) 1,032 (27.5) 1,459 (31.8)
865 (40.6) 1,228 (42.1) 1,363 (36.3) 1,707 (37.2)
039 (95.8) 2,826 (97.0) 3,274 (87.2) 4,119 (89.8)
636 (29.9) 884 (30.3) 993 (26.5) 1,280 (27.9)
00 (9.4) 322 (11.1) 201 (5.4) 289 (6.3)
428 (20.1) 602 (20.7) 495 (13.2) 639 (13.9)
350 (17.7) 457 (15.7) 520 (14.9) 513 (11.2)
128 (6.0) 181 (6.2) 174 (4.6) 188 (4.1)
635 (29.8) 855 (29.3) 739 (19.7) 899 (19.6)
55 (2.6) 50 (1.7) 58 (1.6) 38 (0.8)
50 (2.4) 42 (1.4) 66 (1.8) 56 (1.2)
264 (59.4) 1,776 (61.0) 2,500 (66.6) 3,101 (67.6)
746 (82.0) 2,438 (83.7) 2,976 (79.3) 3,699 (80.6)
950 (91.6) 2,710 (93.0) 3,329 (88.7) 4,157 (90.6)
884 (88.5) 2,589 (88.9) 3,155 (84.1) 4,001 (87.2)
585 (27.5) 917 (31.5) 751 (20.0) 1,049 (22.9)
597 (75.0) 2,254 (77.4) 2,444 (65.1) 3,149 (68.6)
972 (45.7) 1,507 (51.7) 1,679 (44.7) 2,290 (49.9)
ARB ¼ angiotensin receptor blocker; CABG ¼ coronary artery bypass grafting; CKD ¼
ting stent(s); DM ¼ diabetes mellitus; Hb ¼ hemoglobin; MI ¼ myocardial infarction;
ral vascular disease.
TABLE 2 Baseline Data for Patients Receiving BMS for PCI by DM Group and Duration of Clopidogrel Treatment
Insulin-Treated DM (n ¼ 1,229) DM, No Insulin (n ¼ 4,862) No DM (n ¼ 7,990)
Clopidogrel duration, months #12 (n ¼ 784) >12 (n ¼ 445) #12 (n ¼ 3,082) >12 (n ¼ 1,780) #12 (n ¼ 5,430) >12 (n ¼ 2,560)
Age, yrs 63.9  9.9 64.4  9.5 64.9  9.8 65.3  9.5 63.4  10.6 63.7  10.4
Men 764 (97.5) 439 (98.7) 3,032 (98.4) 1,753 (98.5) 5,349 (98.5) 2,515 (98.2)
Comorbidities 5 yrs before to
1 yr after index procedure
Smoking 262 (33.4) 135 (30.3) 1125 (36.5) 651 (36.6) 2,479 (45.7) 1,125 (44.0)
Previous MI 279 (35.6) 170 (38.2) 995 (32.3) 646 (36.3) 1,719 (31.7) 867 (33.9)
Angina 403 (51.4) 223 (50.1) 1,522 (49.4) 879 (49.4) 2,402 (44.2) 1,132 (44.2)
Hypertension 772 (98.5) 437 (98.2) 2,959 (96.0) 1,741 (97.8) 4,797 (88.3) 2,312 (90.3)
COPD 251 (32.0) 140 (31.5) 906 (29.4) 555 (31.2) 1,532 (28.2) 727 (28.4)
CKD 179 (22.8) 112 (25.2) 297 (9.6) 168 (9.4) 271 (5.0) 136 (5.3)
PVD 243 (31.0) 157 (35.3) 722 (23.4) 411 (23.1) 842 (15.5) 401 (15.7)
Anemia, Hb <12 mg/dl 163 (27.1) 126 (28.3) 418 (18.2) 306 (17.2) 628 (15.7) 394 (15.4)
Stroke 90 (11.5) 54 (12.1) 263 (8.5) 130 (7.3) 283 (5.2) 131 (5.1)
Heart failure 385 (49.1) 238 (53.5) 983 (31.9) 589 (33.1) 1,222 (22.5) 572 (22.3)
Previous CABG 27 (3.4) 16 (3.6) 84 (2.7) 47 (2.6) 80 (1.5) 36 (1.4)
Previous PCI 60 (7.7) 24 (5.4) 180 (5.8) 87 (4.9) 213 (3.9) 64 (2.5)
ACS on index admission 465 (59.3) 276 (62.0) 1,861 (60.48) 1,145 (64.3) 3,546 (65.3) 1,749 (68.3)
Baseline medication
Statin or lipid-lowering agent 716 (91.3) 407 (91.5) 2,832 (91.9) 1,663 (93.4) 4,902 (90.3) 2,349 (91.8)
Beta-blocker 730 (93.1) 412 (92.6) 2,829 (91.8) 1,649 (92.6) 4,891 (90.1) 2,294 (89.6)
Calcium-channel blocker 315 (40.2) 195 (43.8) 989 (32.1) 597 (33.5) 1,341 (24.7) 669 (26.1)
ACEI or ARB 640 (81.6) 354 (79.6) 2,498 (81.1) 1,453 (81.6) 3,891 (71.7) 1,824 (71.3)
PPI 404 (51.5) 248 (55.7) 1,395 (45.3) 927 (52.1) 2,370 (43.7) 1,281 (50.0)
Warfarin 86 (11.0) 46 (10.3) 355 (11.5) 126 (7.1) 452 (8.3) 180 (7.0)
Values are mean  SD or n (%).
BMS ¼ bare-metal stent(s); other abbreviations as in Table 1.
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1095insulin (HR: 1.31; p < 0.0001 compared with no DM), and
129 (12%) with no DM. Among patients treated with
BMS, this combined endpoint occurred in 300 patients
(31%) with insulin-treated DM (HR: 2.28; p < 0.0001
compared with no DM), 726 (19%) patients with DM not
requiring insulin (HR: 1.27; p < 0.0001 compared with
no DM), and 233 (15%) of patients without DM.
Compared with 2006, index procedures in earlier
years were associated with a slightly higher risk of
death or MI (HRs ranging from 1.23 to 1.33) with sta-
tistically signiﬁcant differences in death or MI for
years 2002 through 2004 versus 2006 (p ¼ 0.01 to
0.03). For this reason, stent year was included in our
multivariable models.
RISK OF EVENTS ASSOCIATED WITH PROLONGED
CLOPIDOGREL USE. Figures 2 and 3 display the
cumulative event curves for death, and death or MI
for the 3 DM groups stratiﬁed by both duration of
clopidogrel therapy after the index PCI and stent
type. Tables 3 and 4 show the HRs for death, death
or MI, repeat coronary revascularization, stroke,
and severe bleeding from univariate, multivariable,
and propensity-score models. In the multivariable
and propensity-score models, prolonged clopidogrel
treatment remained associated with a lower risk ofdeath and death or MI only in patients with DM
receiving DES (Table 3), but not BMS (Table 4). Pro-
longed clopidogrel treatment was not related to repeat
revascularization, stroke, or severe bleeding. Howev-
er, the number of stroke and severe bleeding events
>12 months after the index PCI was relatively low.
MODELS WITH INTERACTION EFFECTS. Interaction
terms for prolonged clopidogrel treatment and stent
type within each of the 3 DM cohorts were assessed.
Among DM patients not requiring insulin, there was a
signiﬁcant interaction for prolonged clopidogrel
treatment and stent type, with a signiﬁcantly greater
reduction in the risk of death for DES versus BMS
patients (interaction p ¼ 0.03) and death or MI in DES
versus BMS patients (interaction p ¼ 0.005). There
were similar trends in patients with insulin-treated
DM, with prolonged clopidogrel treatment having a
greater effect on risk of death (interaction p ¼ 0.055)
and death or MI (interaction p ¼ 0.19) in patients
receiving DES versus BMS.
SENSITIVITY ANALYSES. The HRs for prolonged clo-
pidogrel treatment, statistical signiﬁcance, and the
conclusions were unchanged in analyses from which
patients with any endpoint in the ﬁrst 12 months were
excluded simulating the DAPT trial (Tables 5 and 6),
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Landmark analyses starting 12 months after the index PCI showing death or myocardial infarction by diabetes mellitus group, stent type, and clopidogrel duration
>12 months versus #12 months. BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); HR ¼ hazard ratio; other abbreviations as in Figure 1.
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1096and for analyses with varying deﬁnitions of stopping
clopidogrel treatment (Online Tables 2 and 3).
DISCUSSION
Patients with DM are at heightened risk of poor clin-
ical outcomes after PCI (12–14), and our analysisrk Analysis for Death
16 20 24 28 32 36 40 44 48
Months After Index PCI
ES) = 0.59, p < 0.01
MS) = 0.89, p = 0.37
Diabetes on Insulin
0 12 16 20 24 28 32 3
Months After Index 
HR (DES) = 0.61, p < 0.01
HR (BMS) = 0.85, p = 0.07
Diabetes No Insuli
537
810
784
445
313
462
670
364
121
161
550
267
2129
2914
3082
1780
1305
1701
2756
1527
Number at Risk Number at Risk
DES, Clopidogrel ≤ 12 Months
DES, Clopidogrel > 12 Months
tarting 12 months after the index PCI showing death by diabetes mellitus gr
iations as in Figures 1 and 2.showed that this risk persisted even in those who
were free of events during ﬁrst year (Central
Illustration). Importantly, this analysis identiﬁed the
interaction of DM and stent type as factors that may
guide long-term DAPT duration. Only patients with
DM receiving a DES had lower risk of death or MI
with prolonged clopidogrel use. Patients without DM6 40 44 48
PCI
n
0 12 16 20 24 28 32 36 40 44 48
Months After Index PCI
HR (DES) = 0.91, p = 0.41
HR (BMS) = 0.86, p = 0.08
No Diabetes
537
606
2386
1190
3753
4589
5430
2560
2313
2549
4909
1390
965
910
4323
981
Number at Risk
BMS, Clopidogrel ≤ 12 Months
BMS, Clopidogrel > 12 Months
oup, stent type, and clopidogrel duration >12 months versus
TABLE 3 Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With >12 Months
Versus #12 Months of Clopidogrel After Index Percutaneous Coronary Revascularization With DES*
Events:
Clopidogrel Duration Univariate Multivariable Adjusted† Propensity Adjusted‡
#12 Months >12 Months HR 95% CI HR 95% CI HR 95% CI
DM treated with insulin
Death 75 (23) 61 (16) 0.59§ 0.42–0.82 0.53§ 0.38–0.75 0.60‡ 0.43–0.85
Death or MI 79 (26) 71 (19) 0.67k 0.49–0.92 0.67 0.48–0.93 0.71 0.61–0.98
CABG or PCI 32 (14) 42 (11) 1.00 0.63–1.59 0.97 0.61–1.55 1.03 0.65–1.65
Stroke 3 (1) 3 (1) 0.71 0.14–3.53 0.76 0.15–3.85 0.76 0.15–3.83
Severe bleed 20 (8) 9 (2) 0.32§ 0.14–0.70 0.28§ 0.13–0.63 0.43 0.20–0.96
DM, no insulin
Death 163 (15) 127 (9) 0.61§ 0.48–0.77 0.60§ 0.48–0.76 0.65§ 0.51–0.82
Death or MI 220 (19) 173 (13) 0.61§ 0.50–0.75 0.60§ 0.49–0.74 0.63§ 0.52–0.77
CABG or PCI 148 (14) 149 (12) 0.81 0.64–1.01 0.81 0.64–1.02 0.83 0.66–1.05
Stroke 16 (1) 14 (1) 0.70 0.34–1.43 0.76 0.37–1.58 0.85 0.41–1.75
Severe bleed 31 (3) 29 (3) 0.73 0.44–1.22 0.73 0.44–1.22 0.99 0.59–1.65
No DM
Death 161 (9) 162 (7) 0.91 0.73–1.14 0.92 0.73–1.14 0.94 0.76–1.18
Death or MI 254 (13) 236 (11) 0.83 0.69–0.99 0.83 0.69–0.99 0.86 0.72–1.03
CABG or PCI 180 (11) 190 (10) 1.00 0.81–1.22 1.02 0.83–1.25 1.04 0.85–1.28
Stroke 15 (1) 13 (0.5) 0.80 0.38–1.68 0.81 0.38–1.71 0.86 0.40–1.82
Severe bleed 29 (2) 30 (1) 0.94 0.56–1.57 0.94 0.56–1.58 1.35 0.80–2.27
Values are n (%) unless otherwise indicated. *Subjects free of the endpoint at 12 months were assessed for risk of the endpoint from 12 months to end of follow-up. †Adjusted
for age, year of stenting, smoking, acute coronary syndrome during index admission, hypertension, peripheral vascular disease, heart failure, chronic kidney disease, warfarin
at discharge, and myocardial infarction, stroke, revascularization, and bleeding during the 1 year after the index procedure. ‡Adjusted for the propensity to use clopidogrel
for >12 months. §p < 0.001. kp < 0.01.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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1097receiving DES or any patient receiving BMS did not
beneﬁt from prolonged clopidogrel use.
COMPARISON WITH THE DAPT RANDOMIZED TRIAL.
These results need to be considered in the context of
several important randomized trials of DAPT duration
after PCI. Compared with the DAPT trial, the largest
randomized trial to date (2,3,15), subjects in our study
had higher rates of a number of risk factors including
hypertension (95% to 98% vs. 76%), smoking (31% to
47% vs. 25%), previous cerebrovascular accident
(4% to 7% vs. 3%), and peripheral vascular disease
(13% to 33% vs. 6%). Not surprisingly, the absolute
rates of major cardiovascular events were also higher
in our 3 groups compared with DAPT (w12% to 20%
vs. 5% to 6% over 3 years). Thus, our population
overall, and the DM subgroups in particular, were at
higher risk than participants in the DAPT study.
Overall, our observational results compare favor-
ably with those of the randomized DAPT study (2,3),
with a 10% to 30% lower risk of major cardiovascular
events by prolonging DAPT treatment >12 months
after PCI (2,3,15). This supports the validity of the
conclusions of our current analysis examining sub-
groups of DM.
In contrast to the DAPT study, we found a lower
risk of all-cause mortality with prolonged clopidogrel
treatment in our overall results (15) and in patientswith DM receiving DES. However, our observational
study had greater statistical power as it included 50%
more patients receiving DES than the DAPT study and
the risk of death was >5 times higher than in the
DAPT study. The higher risk likely reﬂects a more
inclusive “real-world” experience in our cohort, the
longer follow-up in our study, and a higher cardio-
vascular risk of veterans compared with nonveteran
populations. A recent meta-analysis found no differ-
ence in mortality with prolonged clopidogrel use, but
included trials with a diverse range of indications
including medical therapy for cardiovascular disease
and atrial ﬁbrillation and post-PCI patients with much
shorter durations of clopidogrel therapy (17).
In recent months, at least 6 meta-analyses of
randomized trials of prolonged versus short term
DAPT were published (18–23). Four analyses pooled
10 studies including the DAPT trial. The different
meta-analyses include frequentist, Bayesian, and in-
dividual data techniques, as well as intention-to-treat
(risk from the time of the index PCI) and landmark
(risk after a standard treatment time) approaches.
The meta-analyses do not assess high-risk subgroups
such as DM, but overall suggest a lower risk of MI
and a higher risk of all-cause death with prolonged
DAPT. However, the smaller meta-analysis did not
ﬁnd any statistically signiﬁcant differences in these
TABLE 5 Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With >12 Months
Versus #12 Months of Clopidogrel After Percutaneous Coronary Revascularization With DES*
Univariate Multivariable Adjusted† Propensity Adjusted‡
HR 95% CI HR 95% CI HR 95% CI
DM treated with insulin
Death 0.51§ 0.33–0.77 0.50§ 0.32–0.76 0.53§ 0.35–0.81
Death or MI 0.60k 0.42–0.86 0.61k 0.43–0.88 0.63k 0.44–0.91
CABG or PCI 0.92 0.57–1.50 0.93 0.57–1.51 0.96 0.58–1.56
Stroke 0.75 0.15–3.74 0.76 0.15–3.85 0.77 0.15–3.87
Severe bleed 0.31k 0.13–0.76 0.29k 0.12–0.70 0.42 0.17–1.03
DM, no insulin
Death 0.57§ 0.43–0.75 0.56§ 0.42–0.74 0.62§ 0.46–0.82
Death or MI 0.62§ 0.50–0.77 0.60§ 0.48–0.75 0.64§ 0.52–0.80
CABG or PCI 0.81 0.64–1.03 0.82 0.65–1.04 0.84 0.66–1.06
Stroke 0.72 0.33–1.55 0.78 0.36–1.69 0.85 0.39–1.86
Severe bleed 1.24 0.63–2.44 1.26 0.64–2.49 1.63 0.82–3.22
No diabetes mellitus
Death 0.98 0.76–1.25 0.98 0.77–1.26 1.02 0.80–1.31
Death or MI 0.85 0.70–1.03 0.85 0.70–1.03 0.89 0.73–1.08
CABG or PCI 1.00 0.81–1.23 1.02 0.83–1.26 1.05 0.85–1.30
Stroke 0.82 0.38–1.77 0.83 0.38–1.81 0.87 0.40–1.89
Severe bleed 0.97 0.56–1.69 0.96 0.55–1.66 1.41 0.81–2.47
*Subjects with any adverse events in the ﬁrst year were excluded. †Adjusted for age, year of stenting, smoking, acute coronary syndrome during index admission, hypertension,
peripheral vascular disease, heart failure, chronic kidney disease, and warfarin at discharge. ‡Adjusted for the propensity to use clopidogrel for >12 months. §p < 0.001.
kp < 0.01.
Abbreviations as in Tables 1 and 3.
TABLE 4 Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With >12 Months
Versus #12 Months of Clopidogrel After an Index Percutaneous Coronary Revascularization With BMS*
Events Clopidogrel Duration Univariate
Multivariable
Adjusted† Propensity Adjusted‡
#12 Months >12 Months HR 95% CI HR 95% CI HR 95% CI
DM treated with insulin
Death 190 (27) 87 (25) 0.89 0.69–1.15 0.78 0.60–1.02 0.90 0.69–1.16
Death or MI 208 (32) 92 (30) 0.88 0.69–1.13 0.79 0.61–1.02 0.87 0.67–1.12
CABG or PCI 88 (17) 44 (18) 0.97 0.67–1.39 0.95 0.66–1.39 0.87 0.60–1.27
Stroke 16 (3) 6 (2) 0.73 0.29–1.87 0.82 0.31–2.18 0.81 0.31–2.11
Severe bleed 27 (4) 13 (4) 0.90 0.46–1.74 0.77 0.39–1.54 0.88 0.45–1.73
DM, no insulin
Death 405 (15) 179 (13) 0.85 0.71–1.01 0.83 0.70–1.00 0.89 0.74–1.07
Death or MI 498 (19) 228 (17) 0.88 0.75–1.03 0.87 0.74–1.02 0.88 0.75–1.04
CABG or PCI 324 (15) 171 (15) 1.03 0.86–1.24 1.08 0.89–1.31 1.00 0.82–1.21
Stroke 53 (2) 18 (1) 0.65 0.38–1.11 0.68 0.39–1.19 0.69 0.40–1.19
Severe bleed 71 (3) 31 (2) 0.83 0.54–1.27 0.87 0.56–1.34 0.99 0.64–1.54
No DM
Death 526 (11) 193 (10) 0.86 0.73–1.02 0.84 0.71–1.00 0.89 0.75–1.06
Death or MI 711 (15) 268 (14) 0.88 0.77–1.02 0.86 0.75–1.00 0.88 0.76–1.02
CABG or PCI 474 (12) 200 (12) 1.03 0.87–1.21 1.08 0.91–1.28 0.97 0.81–1.15
Stroke 51 (1) 18 (1) 0.84 0.49–1.44 0.87 0.50–1.52 0.90 0.52–1.58
Severe bleed 100 (2) 37 (2) 0.86 0.59–1.25 0.90 0.61–1.33 0.92 0.62–1.37
Values are n (%) unless otherwise indicated. *Subjects free of the endpoint at 12 months were assessed for risk of the endpoint from 12 months to end of follow-up. †Adjusted
for age, year of stenting, smoking, acute coronary syndrome during index admission, hypertension, peripheral vascular disease, heart failure, chronic kidney disease, warfarin at
discharge, and myocardial infarction, stroke, revascularization, and bleeding during the 1 year after the index procedure. ‡Adjusted for the propensity to use clopidogrel
for >12 months.
Abbreviations as in Tables 1, 2, and 3.
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TABLE 6 Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With >12 Months
Versus #12 Months of Clopidogrel After Index Percutaneous Coronary Revascularization With BMS*
Univariate Multivariable Adjusted† Propensity Adjusted‡
HR 95% CI HR 95% CI HR 95% CI
DM treated with insulin
Death 0.83 0.61–1.12 0.70 0.51–0.97 0.85 0.62–1.16
Death or MI 0.94 0.71–1.23 0.82 0.62–1.08 0.93 0.70–1.23
CABG or PCI 0.96 0.66–1.39 0.95 0.65–1.39 0.86 0.59–1.27
Stroke 0.68 0.24–1.89 0.73 0.26–2.08 0.72 0.26–2.03
Severe bleed 0.67 0.26–1.70 0.58 0.22–1.54 0.70 0.28–1.80
DM, no insulin
Death 0.78§ 0.64–0.96 0.77 0.62–0.95 0.82 0.66–1.02
Death or MI 0.84 0.71–1.00 0.83 0.69–0.99 0.85 0.71–1.01
CABG or PCI 0.98 0.81–1.19 1.03 0.84–1.26 0.94 0.77–1.15
Stroke 0.55 0.29–1.04 0.58 0.30–1.13 0.56 0.29–1.08
Severe bleed 0.72 0.44–1.19 0.77 0.46–1.30 0.89 0.52–1.50
No DM
Death 0.87 0.73, 1.05 0.86 0.71, 1.04 0.91 0.75–1.10
Death or MI 0.89 0.76–1.03 0.86 0.73–1.00 0.89 0.76–1.04
CABG or PCI 1.02 0.86–1.21 1.08 0.91–1.29 0.96 0.80–1.15
Stroke 0.93 0.53–1.63 0.97 0.55–1.73 0.99 0.55–1.76
Severe bleed 0.72 0.47–1.11 0.76 0.49–1.18 1.79 0.51–1.24
*Subjects with any adverse events in the ﬁrst year were excluded. †Adjusted for age, year of stenting, smoking, acute coronary syndrome during index admission, hypertension,
peripheral vascular disease, heart failure, chronic kidney disease, and warfarin at discharge. ‡Adjusted for the propensity to use clopidogrel for >12 months.
Abbreviations as in Tables 1, 2, and 3.
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1099endpoints, and all analyses found no effect on cardiac
mortality when this was assessed. Overall, our study
has 10% to 300% more deaths in our DES subgroup
and 240% to 610% more deaths overall than the total
number of deaths in these meta-analyses. This en-
ables us to assess the value of prolonged clopidogrel
use in the important subgroup of DM with sufﬁcient
statistical power. Identifying subgroups of patients
where the risk beneﬁt ratio of prolonged DAPT is
more favorable may help to rationalize post-PCI ther-
apy. In another example of this approach, patients in
the DAPT trial with an acute coronary syndrome at
their index PCI had a greater reduction in major
adverse cardiovascular events from prolonged DAPT
than those with stable syndromes (24). However,
this analysis lacked the power to assess individual
endpoints in these subgroups.
Newer second-generation DES may modify the
beneﬁt of prolonged clopidogrel. First-generation DES
were the only DES in our study and the TL-PAS (TAXUS
Liberte Post Approval Study) (2) and accounted for
30% of DES in the DAPT study. In the DAPT study, the
reduction in risk of MI with prolonged clopidogrel use
tended to be lower in second- versus ﬁrst-generation
DES. Other randomized trials concluded that there is
little difference between 6 months of DAPT and 12 or
24 months of DAPT (4–10). However, many of these
studies are much smaller than DAPT with lower sta-
tistical power. Nevertheless, they have led touncertainty and concern in prolonging DAPT for
several years after PCI in every patient. Our study
provides evidence that prolonged DAPT can be
tailored to speciﬁc patient and stent characteristics.
OTHER ENDPOINTS. Prolonged clopidogrel treat-
ment did not alter the rate of repeat coronary revas-
cularization for either the stent type or DM group, a
result similar to the TL-PAS for revascularization not
related to MI (2). Although the number of strokes
and serious bleeding events was small, there was no
suggestion of an increased risk in these other impor-
tant clinical endpoints with prolonged clopidogrel.
The lack of a consistent effect on serious bleeding
with prolonged clopidogrel treatment may reﬂect our
deﬁnition and the exclusion of patients with this event
in the ﬁrst year after PCI, which likely selected patients
with a lower risk of bleeding in the 1- to 4-year time
frame of this study. This emulates the clinical situa-
tion, as most physicians would not consider prolong-
ing clopidogrel treatment in patients with serious
bleeding events in the ﬁrst year after PCI. Our deﬁni-
tion of bleeding based on major bleeding deﬁned by
ICD-9 codes included intracranial and intraocular
hemorrhage and is less likely to identify mild or mod-
erate bleeding events. These events are similar to the
more severe bleeding categories used in the DAPT
study that were also uncommon and not increased
with prolonged clopidogrel use over a similar time
frame (3). Other studies suggest that patients with DM
CENTRAL ILLUSTRATION Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging
Clopidogrel After Coronary Stenting
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1100may beneﬁt from more intensive antiplatelet therapy
without an increase in bleeding. In the TRITON-TIMI
38 (Therapeutic Outcomes by Optimizing Platelet In-
hibition with Prasugrel-Thrombolysis In Myocardial
Infarction) study of prasugrel versus clopidogrel in
acute coronary syndromes, an increase in bleeding
occurred with prasugrel in patients without DM but
not those with DM (25). However, in our analysis, we
cannot exclude an increased risk of minor or moderate
bleeding with prolonged clopidogrel treatment.
STUDY LIMITATIONS. The results of this analysis
are derived from several administrative databases and
could be affected by unknown confounders. Patients
in this large analysis were not randomized toprolonged clopidogrel or placebo treatment, and
therefore we may not have captured unknown fac-
tors inﬂuencing extended clopidogrel use beyond
12 months and the clinical outcomes. However, both
multivariable and propensity-adjusted analyses had
HRs consistent with the univariate analyses, suggest-
ing no major effects from known confounders. This
study did not include the use of second-generation
DES and the more potent antiplatelet agents as these
were introduced after the time frame of this study.
CONCLUSIONS
The present study demonstrates that for DM patients
who have not experienced an adverse event within the
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Continuation of clopidogrel therapy beyond 12 months
should be considered for patients with DM undergoing PCI
with DES.
TRANSLATIONAL OUTLOOK: Future randomized trials
should include sufﬁciently powered, pre-speciﬁed subgroup an-
alyses to determine speciﬁcally whether patients with DM gain
greater beneﬁt from extended adjunctive antiplatelet therapy
after PCI than nondiabetic patients and explore the potential
pathophysiological mechanisms underlying this difference.
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1101ﬁrst 12 months after the PCI, extending clopidogrel
treatment >12 months after PCI is associated with a
reduced risk of very late death or MI only in those
receiving DES. There was no such beneﬁt for prolonged
clopidogrel treatment in DM patients receiving BMS or
patients without DM treated with either stent type.
Large randomized trials of ﬁrst- and second-generation
DES should examine outcomes by subgroups of DM to
further assess whether this could be a useful indication
for prolonging clopidogrel therapy after DES.
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